In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually sickness progression or the contributors are unable to tolerate the study drugs. - "Our study discovered the vital part of the KLF16/MYC regulatory axis in https://abbv-744-brd4-inhibitor-m91245.gynoblog.com/31290786/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained